Prostate CancerPhase 3NCT00667888

A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

A Phase 3 study testing Conventional Fractionated Intensity Modulated Radiotherapy and Hypofractionated Intensity Modulated Radiotherapy in people with Prostate Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record

Search all trials

Trial summary

The goal of this clinical research study is to compare using external beam radiotherapy with intensity modulated beams for fewer days at a higher dose per day to the same type of therapy for more days at a lower dose per day in the treatment of prostate cancer. Read more about this study

Who is it for?: Any age, men only
Conditions the study is for: Prostate Cancer
What is being tested?: Conventional Fractionated Intensity Modulated Radiotherapy and Hypofractionated Intensity Modulated Radiotherapy
Type of treatment: Surgery or procedure
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 225 participants
Where: 1 siteUnited States
Study dates: 3 Jan 2001to Oct 2021
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages Any age
Men only
No healthy volunteers
Child, Adult, Older adult

Who may be able to join

Biopsy proof of adenocarcinoma of the prostate.
Bone scan (If PSA >10 ng/ml or T3 disease) within 3 months of starting androgen ablation or signing protocol consent if no androgen ablation.
CT-scan of pelvis (If Stage T3 disease) within 3 months of starting androgen ablation or signing protocol consent if no androgen ablation.
Suitable medical condition; Zubrod <2.
Pretreatment PSA </=20 ng/ml. If PSA <4, must have Gleason greater than or equal to 7 and/or Stage T2b-T2c. PSA within 30 days of signing protocol consent. If neoadjuvant androgen ablation has been given, then the preandrogen ablation PSA should be used for stratification.
Clinical (palpable) Stage T1b - T3b disease (1992 AJCC staging system).

Show all 12Show fewer

While a transrectal ultrasound will be obtained before treatment, the staging will not be based on these findings. If palpable T3 disease is present, then must have Gleason score <8 and pretreatment PSA less than or equal to 10 ng/ml
Gleason score <10.
If Gleason score 8 or 9, then must have stage T1/T2 disease and pretreatment PSA less than or equal to 10 ng/ml.
The patient must be able to understand the protocol and adhere to follow-up at 6-month intervals for the first 2 years and at yearly intervals thereafter.
Informed consent must be given.
Patients randomized to Arm 1 may also participate in protocol 2004-0428.

Who cannot join

Prior pelvic radiotherapy.
Greater than 4 months of prior hormone ablation therapy.
Prior or planned radical prostate surgery.
Clinical, radiographic or pathologic evidence of nodal or distant metastatic disease.
Concurrent, active malignancy, other than nonmetastatic skin cancer or early stage -chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma). If a prior malignancy is in remission for greater than or equal to 5 yr then the patient is eligible.
Zubrod status greater than or equal to 2.

Show all 9Show fewer

Pretreatment PSA >20 ng/ml.
Gleason score of 10.
Palpable stage T3c (seminal vesicle involvement) or T4 disease.

Trial locations and contacts

1 site in 1 country.

United States1 site

University of Texas MD Anderson Cancer Center
Houston, Texas, 77030

Other trials in United States

About this study

Read the detailed description

Patients in this study will be randomly picked (as in the toss of a coin) to be in one of two treatment groups. There is an equal chance of being in either group.

Patients in Group 1 will be treated with intensity modulated radiotherapy (IMRT). These patients will receive 42 treatments, 5 days per week, over 8.5 weeks. This method has become the standard treatment at M.D. Anderson Cancer Center.

Patients in Group 2 will also be treated with IMRT. However, these patients will only receive 30 treatments, 5 days per week, over 6 weeks. The dose per day for Group 2 patients is higher than for Group 1 and has the possibility of killing more tumor cells.

Each external beam treatment requires about 10-20 minutes. However, patients can expect to spend 20 - 30 minutes on the treatment table because imaging measurements of prostate position will be done before each treatment. The total time in the radiation department each treatment day will be about an hour.

After the radiotherapy is completed, patients will have a PSA blood test every 3 months for 2 years, then every 6 months for Years 3 - 5, then annually. They will be examined every 6 months during the first 2 years beginning 3 months after the completion of treatment, then annually. A needle biopsy of the prostate will be performed if these tests suggest recurrence.

This is an investigational study. 225 patients will take part in this study. This study will take place at M. D. Anderson and possibly some affiliated hospitals.

Conditions: Prostate Cancer
Being tested: Conventional Fractionated Intensity Modulated Radiotherapy, Hypofractionated Intensity Modulated Radiotherapy
Keywords: Prostate Cancer, Radiation, Radiotherapy, Intensity Modulated Radiotherapy, IMRT, Hypofractionated Intensity Modulated Radiotherapy, HIMRT
Medical subject headings: Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Conventional Fractionated Intensity Modulated RadiotherapyRadiation
Also called IMRT
A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
Hypofractionated Intensity Modulated RadiotherapyRadiation
Also called HIMRT
A total dose of 72 Gy will be delivered in 30 fractions to the PTV.

Study groups in NCT00667888
Study group	Role	What they receive
Intensity Modulated Radiotherapy (IMRT)	Active comparator	A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV). Receives: Radiation: Conventional Fractionated Intensity Modulated Radiotherapy
Hypofractionated Intensity Modulated Radiotherapy (HIMRT)	Experimental	A total dose of 72 Gy will be delivered in 30 fractions to the PTV. Receives: Radiation: Hypofractionated Intensity Modulated Radiotherapy

What is being measured

The primary outcome is the main question the study is designed to answer.

Conventional Radiotherapy (CIMRT) Versus Hypofractionated Radiotherapy (HIMRT)
To determine the progression of the number of participants who failed treatment after receiving (CIMRT) versus (HIMRT). PSA measured on (CIMRT) and (HIMRT) for each participant on both arms. Failure was defined as Prostate-specific antigen (PSA) failure using the Phoenix definition of nadir plus 2 ng/ml, or initiation of salvage therapy.
Measured: 8.5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

3 Jan 2001Oct 2021

First posted28 Apr 2008 (estimated)
Study start3 Jan 2001
Primary completion12 Oct 2015
Study completionOct 2021 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (2)Papers the sponsor has linked to this study.
Other trials for Prostate CancerStudies of the same condition, open and under way.
More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 225 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT00667888
Sponsor's protocol ID: ID00-381
Other IDs: NCI-2010-01456
Status last verified: Jan 2021
First submitted: 24 Apr 2008
Last updated: 25 Jan 2021
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes

Publications

Hassanzadeh C, Kuban D, Pasyar S, Bassett R, Troncoso P, Ansari M, Schlembach P, McGuire S, Nguyen Q, Frank S, Mok H, Mohamad O, Park R, Tang C, Du W, Kudchadker R, Choi S, Hoffman K. Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial. J Clin Oncol. 2025 Jun 20;43(18):2044-2048. doi: 10.1200/JCO-24-02057. Epub 2025 May 14.
PubMed 40367400
Kim S, Kong JH, Lee Y, Lee JY, Kang TW, Kong TH, Kim MH, You SH. Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer. Cochrane Database Syst Rev. 2023 Mar 8;3(3):CD012817. doi: 10.1002/14651858.CD012817.pub2.
PubMed 36884035

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence

All Prostate Cancer trials

Study at a glance

From the registry record, last updated by the sponsor on 25 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
ClinicalTrials.gov ID: NCT00667888
Acronym / sponsor ID: ID00-381
Conditions: Prostate Cancer
Keywords: Prostate Cancer, Radiation, Radiotherapy, Intensity Modulated Radiotherapy, IMRT, Hypofractionated Intensity Modulated Radiotherapy, HIMRT
Phase: Phase 3
Study type: Interventional
Recruitment status: Unknown status
Enrolment: 225 participants (actual)
Lead sponsor: M.D. Anderson Cancer CenterUniversity, hospital or other
Study start: 3 Jan 2001 (actual)
Primary completion: 12 Oct 2015 (actual)
Study completion: Oct 2021 (estimated)
First posted: 28 Apr 2008 (estimated)
Results: Posted 25 Jan 2021

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Patients in this study will be randomly picked (as in the toss of a coin) to be in one of two treatment groups. There is an equal chance of being in either group.

This is an investigational study. 225 patients will take part in this study. This study will take place at M. D. Anderson and possibly some affiliated hospitals.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Intensity Modulated Radiotherapy (IMRT)	Active comparator	Radiation: Conventional Fractionated Intensity Modulated RadiotherapyA total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
Hypofractionated Intensity Modulated Radiotherapy (HIMRT)	Experimental	Radiation: Hypofractionated Intensity Modulated RadiotherapyA total dose of 72 Gy will be delivered in 30 fractions to the PTV.

Who may qualify

Sex: Male only
Healthy volunteers: Not accepted
Age groups: Child, Adult, Older adult

Key inclusion criteria (12 listed)

Biopsy proof of adenocarcinoma of the prostate.
Bone scan (If PSA >10 ng/ml or T3 disease) within 3 months of starting androgen ablation or signing protocol consent if no androgen ablation.
CT-scan of pelvis (If Stage T3 disease) within 3 months of starting androgen ablation or signing protocol consent if no androgen ablation.
Suitable medical condition; Zubrod <2.
Pretreatment PSA </=20 ng/ml. If PSA <4, must have Gleason greater than or equal to 7 and/or Stage T2b-T2c. PSA within 30 days of signing protocol consent. If neoadjuvant androgen ablation has been given, then the preandrogen ablation PSA should be used for stratification.

Key exclusion criteria (9 listed)

Prior pelvic radiotherapy.
Greater than 4 months of prior hormone ablation therapy.
Prior or planned radical prostate surgery.
Clinical, radiographic or pathologic evidence of nodal or distant metastatic disease.
Concurrent, active malignancy, other than nonmetastatic skin cancer or early stage -chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma). If a prior malignancy is in remission for greater than or equal to 5 yr then the patient is eligible.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Conventional Fractionated Intensity Modulated RadiotherapyAlso: IMRTA total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).	Radiation	Intensity Modulated Radiotherapy (IMRT)
Hypofractionated Intensity Modulated RadiotherapyAlso: HIMRTA total dose of 72 Gy will be delivered in 30 fractions to the PTV.	Radiation	Hypofractionated Intensity Modulated Radiotherapy (HIMRT)

Primary outcome

Conventional Radiotherapy (CIMRT) Versus Hypofractionated Radiotherapy (HIMRT)
Time frame: 8.5 years
To determine the progression of the number of participants who failed treatment after receiving (CIMRT) versus (HIMRT). PSA measured on (CIMRT) and (HIMRT) for each participant on both arms. Failure was defined as Prostate-specific antigen (PSA) failure using the Phoenix definition of nadir plus 2 ng/ml, or initiation of salvage therapy.

Results and safety

Results posted to the registry on 25 Jan 2021, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Arm 1: (CIMRT) Conventional Radiotherapy	111	101
Arm 2: (HIMRT) Hypofractionated Radiotherapy	111	102

Primary outcome: Conventional Radiotherapy (CIMRT) Versus Hypofractionated Radiotherapy (HIMRT)

Time frame: 8.5 years. Count of participants. Unit: Participants

Measure	Arm 1: (CIMRT) Conventional Radiotherapy n = 101	Arm 2: (HIMRT) Hypofractionated Radiotherapy n = 102
Value	21	10

Adverse events

Time frame: 8.5 years. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Arm 1: (CIMRT) Conventional Radiotherapy	0 of 101 (0%)	56 of 101 (55.4%)	1 of 101
Arm 2: (HIMRT) Hypofractionated Radiotherapy	0 of 102 (0%)	79 of 102 (77.5%)	1 of 102

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2021.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 40367400Hassanzadeh C, Kuban D, Pasyar S, Bassett R, Troncoso P, Ansari M, Schlembach P, McGuire S, Nguyen Q, Frank S, Mok H, Mohamad O, Park R, Tang C, Du W, Kudchadker R, Choi S, Hoffman K. Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial. J Clin Oncol. 2025 Jun 20;43(18):2044-2048. doi: 10.1200/JCO-24-02057. Epub 2025 May 14.
Derived from this study: PubMed 36884035Kim S, Kong JH, Lee Y, Lee JY, Kang TW, Kong TH, Kim MH, You SH. Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer. Cochrane Database Syst Rev. 2023 Mar 8;3(3):CD012817. doi: 10.1002/14651858.CD012817.pub2.
MD Anderson Cancer CenterLink provided by the sponsor.

Related trials for Prostate Cancer

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Deborah A. Kuban, MD principal investigator

M.D. Anderson Cancer Center

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 25 Jan 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Conventional Radiotherapy (CIMRT) Versus Hypofractionated Radiotherapy (HIMRT) (time frame: 8.5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00667888, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.